Your AI-Trained Oncology Knowledge Connection!
Experts discuss that for patients with chronic lymphocytic leukemia intolerant to the BTK inhibitor ibrutinib, due to side effects like arthralgia, myalgia, or diarrhea, switching to a second-generation BTK inhibitor can be effective and better tolerated.
A medical oncologist discusses data from the LIBRETTO-431 clinical trial looking at first-line selpercatinib vs chemotherapy and pembrolizumab in RET fusion–positive NSCLC.
Craig Cole, MD, reviews data from DREAMM-3 on the efficacy and safety of single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma.
Sandip P. Patel, MD, reviews recent data from the PAPILLON study investigating amivantamab plus chemotherapy in the first line for patients with EGFR exon 20 insertion–mutated advanced NSCLC.
Experts on multiple myeloma discuss the clinical applications of ixazomib-lenalidomide-dexamethasone combination therapy.
Joselle Cook, M.B.B.S., discusses the RedirecTT-1 trial combining teclistamab and talquetamab for patients with relapsed/refractory multiple myeloma, noting high response rates even in high-risk myeloma but concerns about long-term resistance.
Dr Binod Dhakal discusses response rates and toxicities seen with recently approved bispecific antibodies talquetamab in patients with heavily pretreated multiple myeloma, noting high response rates even after CAR-T, but also unique side effects.
Drs Ahn and Cohen discuss the treatment of colorectal cancer, reviewing the available options and describing factors influencing treatment choice and use of maintenance therapy after initial response.
Insight into the latest updates on three approved bispecific therapies in the context of relapsed and refractory multiple myeloma, including teclistamab, talquetamab, and elranatamab, discussing response rates, administration, and side effects.
A review of clinical trial data on bispecific antibodies in multiple myeloma and clinical insights on how these medications have changed clinical practice.
Stacy A. Cohen, MD, provides an overview of colorectal cancer, noting increasing incidence in younger patients; Christina S. Wu, MB, BCh, MD, discussed possible reasons for more colorectal cancer in younger people, including genetic predisposition and exposures, though the causes remain unclear.
Dive into a compelling case study showcasing the effective use of talquetamab therapy in the management of relapsed multiple myeloma, discussing responses, side effects, and treatment outcomes.
The panel reviews the profiles of 2 patients with multiple myeloma and provides their initial thoughts regarding treatment approaches.
The Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital includes a social worker, nurse practitioners, a medical oncologist, a radiation oncologist, and surgeons, says Claudia Tellez, MD.
The goal of creating the Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital is to establish a safe space for Hispanic patients, says Claudia Tellez, MD.
Dr Sai-Hong Ou highlights the significance of next-generation sequencing for detecting EGFR mutations in patients with non-small cell lung cancer and the potential for adjuvant testing regardless of disease stage.
In this program, Sai-Hong Ou, MD, PhD, discusses biomarker testing for precision medicine in non-small cell lung cancer, emphasizing the importance of both tissue and blood-based genotyping, and the need for a complementary approach due to potential limitations in detecting targetable mutations.
Expert discussion focused on approved therapies for first-line kidney cancer treatment including combination therapies, immunotherapy, and tyrosine kinase inhibitors (TKIs) in various clinical scenarios.
Join Wenxin (Vincent) Xu, MD, and his team at Dana-Farber Cancer Institute as they explore strategies for diagnosing and stratifying renal cell carcinoma, reviewing a clinical scenarios and best practices in workup.
Several factors may contribute to the low Hispanic breast cancer population at Northwestern Memorial Hospital, including a lack of resources and a focus on other disease types.
An expert discussion surrounding the evolving treatment landscape for relapsed or refractory follicular lymphoma in the third-line setting and beyond.
Faculty review potential adverse events (AEs) seen in patients receiving treatment with bispecific antibodies and discuss preferred strategies for AE management.
John C. Molina, MD, EdM, reviews data from the 3-year update from the OPTIC study, and other experts offer their impressions.
Experts in the field of chronic myeloid leukemia discuss the role of asciminib in the overall treatment landscape.
Medical expert outlines that resistance to BTK inhibitors in patients with chronic lymphocytic leukemia is commonly mediated by mutations in BTK or phospholipase Cγ2 proteins, and highlights new, unique mutation patterns in zanubrutinib; he also mentions emerging therapies including noncovalent BTK inhibitors and clinical trials focusing on BTK degradation for additional lines of therapy.
The panel discusses key data from the ALPINE trial comparing ibrutinib and zanubrutinib in relapsed chronic lymphocytic leukemia, showing a progression-free survival favoring zanubrutinib; Ricardo Parrondo, MD, suggests this may be due to its better toxicity profile, leading to longer patient adherence.
Faiz Answer, MD, FACP, reviews data from the REMIX study on the real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.
Experts in the field of multiple myeloma discuss data from a retrospective study on patients with multiple myeloma.
Dr Luciano Costa discusses treatment options for patients with multiple myeloma with early vs late relapse, noting that those with early aggressive relapse have limited options and often rapidly exhaust available therapies, emphasizing the need for newer agents like bispecific antibodies.
Binod Dhakal, MD, presents the case of a young man with aggressive relapsed multiple myeloma to the panel for discussion.
